Health · Medical Research · 1 hr ago
Early trial finds prostate cancer drug reduced tumor activity and pain
A Yale-led early clinical trial tested bavdegalutamide in advanced prostate cancer that had continued growing despite hormone treatment.
The disease, called metastatic castration-resistant prostate cancer, has spread beyond the prostate and is difficult to treat.
Hormone therapies reduce testosterone, but this drug takes a different approach by using the cell’s protein-recycling system to remove androgen receptors that help drive cancer growth.
In the trial, researchers saw reductions in PSA and tumor activity, as well as improvements in pain among some patients.
Patients whose cancers had certain androgen receptor mutations showed greater PSA reductions, suggesting the drug may work better for some genetic profiles.
The findings are early, and the trial does not establish a cure.
Researchers are also testing ARV-766, a related drug designed to work against a broader range of androgen receptor mutations.
An early clinical trial found that bavdegalutamide reduced tumor activity and pain in patients with advanced prostate cancer.
The drug was tested in patients whose cancer had continued to grow despite low testosterone and who had already received treatment.
Bavdegalutamide works by removing androgen receptors that help testosterone drive cancer growth.
Patients with certain androgen receptor mutations had greater reductions in prostate-specific antigen.
Researchers are also testing a second PROTAC drug, ARV-766, in Phase I and Phase II trials.
- Who
- Researchers led by Yale tested bavdegalutamide in patients with metastatic castration-resistant prostate cancer.
- What
- An early trial found reductions in tumor activity and pain.
- When
- The study was published Oct. 9; the year is not stated.
- Where
- The trial was led by Yale. The location of the trial is not stated.
- Why
- The drug was designed to target androgen receptors and potentially bypass resistance to hormone therapy.
This story does not have two clearly opposing sides.
Researchers assessed dosing and safety and found that a daily dose of 420 milligrams was safe in the patients studied.
Researchers measured prostate-specific antigen before and after treatment to assess changes in disease activity.
Researchers and clinical collaborators began testing a second PROTAC, ARV-766, in Phase I and Phase II trials.
- Drug
- Bavdegalutamide, also called ARV-110
- Trial
- Phase I/Phase II
- Phase I dose
- 420 milligrams daily
- Patient group
- Metastatic castration-resistant prostate cancer
- Mutation findings
- T878 and/or H875 mutations were linked to greater PSA reductions
What people are saying
These are the parameters that indicate a positive response.
This is a first-in-class drug for prostate cancer.